Clinical Trial

Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study proposes that the addition of statins reduces the treatment delays or early discontinuations secondary to cardiotoxicity in patients with Stage I-III HER2 positive breast being treated with anti-HER2 therapy.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-09-26; most recent amendment 2025-11-13.
Status change: Suspended → Recruiting 2023-02-21
Trial Details
NCT Number NCT05559164
Lead Sponsor Rutgers, The State University of New Jersey
Conditions Cardiac Toxicity, Early-stage Breast Cancer
Enrollment 60 participants
Start Date 2022-09-19
Primary Completion 2026-09-01 (estimated)
Study Completion 2027-03-01 (estimated)
Updated on ClinicalTrials.gov 2025-11-14